All-Trans Retinoic Acid Attenuates Transmissible Gastroenteritis Virus-Induced Inflammation in IPEC-J2 Cells via Suppressing the RLRs/NF‐κB Signaling Pathway

Transmissible gastroenteritis virus (TGEV) infection can cause transmissible gastroenteritis (TGE), especially in suckling piglets, resulting in a significant economic loss for the global pig industry. The pathogenesis of TGEV infection is closely related to intestinal inflammation. All-trans retinoic acid (ATRA) has anti-inflammatory activity and immunomodulatory properties, but it is unclear whether ATRA can attenuate the inflammatory response induced by TGEV. This study aimed to investigate the protective effect of ATRA on TGEV-induced inflammatory injury in intestinal porcine epithelial cells (IPEC-J2) and to explore the underlying molecular mechanism. The results showed that TGEV infection triggered inflammatory response and damaged epithelial barrier integrity in IPEC-J2 cells. However, ATRA attenuated TGEV-induced inflammatory response by inhibiting the release of pro-inflammatory cytokines, including IL-1β, IL-6, IL-8 and TNF-α. ATRA also significantly reversed the reduction of ZO-1 and Occludin protein levels induced by TGEV infection and maintained epithelial barrier integrity. Moreover, ATRA treatment significantly prevented the upregulation of IкBα and NF-κB p65 phosphorylation levels and the nuclear translocation of NF-кB p65 induced by TGEV. On the other hand, treatment of TGEV-infected IPEC-J2 cells with the NF-κB inhibitors (BAY11-7082) significantly decreased the levels of inflammatory cytokines. Furthermore, ATRA treatment significantly downregulated the mRNA abundance and protein levels of TLR3, TLR7, RIG-I and MDA5, and downregulated their downstream signaling molecules TRIF, TRAF6 and MAVS mRNA expressions in TGEV-infected IPEC-J2 cells. However, the knockdown of RIG-I and MDA5 but not TLR3 and TLR7 significantly reduced the NF-κB p65 phosphorylation level and inflammatory cytokines levels in TGEV-infected IPEC-J2 cells. Our results indicated that ATRA attenuated TGEV-induced IPEC-J2 cells damage via suppressing inflammatory response, the mechanism of which is associated with the inhibition of TGEV-mediated activation of the RLRs/NF‐κB signaling pathway.

Transmissible gastroenteritis virus (TGEV) infection can cause transmissible gastroenteritis (TGE), especially in suckling piglets, resulting in a significant economic loss for the global pig industry. The pathogenesis of TGEV infection is closely related to intestinal inflammation. All-trans retinoic acid (ATRA) has anti-inflammatory activity and immunomodulatory properties, but it is unclear whether ATRA can attenuate the inflammatory response induced by TGEV. This study aimed to investigate the protective effect of ATRA on TGEV-induced inflammatory injury in intestinal porcine epithelial cells (IPEC-J2) and to explore the underlying molecular mechanism. The results showed that TGEV infection triggered inflammatory response and damaged epithelial barrier integrity in IPEC-J2 cells. However, ATRA attenuated TGEV-induced inflammatory response by inhibiting the release of pro-inflammatory cytokines, including IL-1b, IL-6, IL-8 and TNF-a. ATRA also significantly reversed the reduction of ZO-1 and Occludin protein levels induced by TGEV infection and maintained epithelial barrier integrity. Moreover, ATRA treatment significantly prevented the upregulation of IкBa and NF-kB p65 phosphorylation levels and the nuclear translocation of NF-кB p65 induced by TGEV. On the other hand, treatment of TGEV-infected IPEC-J2 cells with the NF-kB inhibitors (BAY11-7082) significantly decreased the levels of inflammatory cytokines. Furthermore, ATRA treatment significantly downregulated the mRNA abundance and protein levels of TLR3, TLR7, RIG-I and MDA5, and downregulated their downstream signaling molecules TRIF, TRAF6 and MAVS mRNA expressions in TGEV-infected IPEC-J2 cells. However, the knockdown of RIG-I and MDA5 but not TLR3 and TLR7 significantly reduced the NF-kB p65 phosphorylation level and inflammatory cytokines levels in TGEV-infected

INTRODUCTION
Transmissible gastroenteritis (TGE) is a highly contagious enteric disease caused by transmissible gastroenteritis virus (TGEV) infection, with clinical symptoms typified by dehydration, vomiting and severe diarrhea in piglets (1). TGEV is an enveloped, single-stranded, positive-sense RNA virus, belonging to the Coronaviridae family in the order Nidovirales (2). TGEV can infect pigs of various breeds and ages, especially suckling piglets under two weeks of age are the most susceptible, and the mortality rate possibly reaching up to 100%, resulting in significant economic losses to the pig breeding industry (3). Porcine small intestinal epithelial cells are the main target cells of TGEV infection. TGEV replicates in enterocytes covering the villi of the porcine small intestine, causing severe gastroenteritis and impairing the integrity of the gastrointestinal mucosa in infected piglets (4). Consistent with the pathological changes in vivo, TGEV infection also induces morphological and biochemical changes of host cells in vitro. Previous studies have shown that TGEV could impair the barrier integrity of IPEC-J2 cells by down-regulating the expression of proteins involved in tight and adhesion junctions (5). A large number of studies have shown that the pathogenesis of coronavirus infection is closely related to excessive inflammatory response, which is regulated by a variety of signal cascades, including NF-kB, STAT, MAPKs and so on (6,7). Previous studies found that the mRNA levels of proinflammatory cytokines IL-1b, IL-6 and TNF-a were significantly increased in the jejunum of piglets infected with TGEV (8). Furthermore, studies have reported that TGEV infection induces inflammation in ST cells and IPEC-J2 cells by activating the NF-kB signaling pathway (9). These evidences indicate that the inflammation of the small intestine may be an important event in the pathogenesis of TGEV infection. At present, vaccination is the main technical means to prevent and treat TGEV infection (10). However, current traditional vaccines, whether inactivated or attenuated, cannot provide full protection for pigs due to the genetic variation of TGEV (11). Therefore, the discovery and development of novel, secure anti-TGEV agents and effective methods for controlling TGEV infection is necessary for the current pig industry.
All-trans retinoic acid (ATRA) is an active metabolite of VA and can regulate a wide range of physiological and biological processes through the action of retinoid acid receptor (RAR) (12). The primary biological functions of ATRA include regulating embryonic development, reproduction, vision, cell growth and differentiation (13,14). In addition, recent studies have shown that as an immunomodulator, ATRA also plays important roles in regulating immune response and maintaining intestinal homeostasis, especially under stress conditions (15). ATRA has been indicated to be impactful in many intestinal inflammation models (16,17). He (20). These results indicated that ATRA has the effect of relieving intestinal inflammation. In addition, previous studies reported that ATRA can attenuate virus-induced inflammatory response (21)(22)(23). However, it is unclear whether ATRA can attenuate TGEVinduced intestinal inflammatory damage.
Therefore, this study aimed to investigate the protective effect of ATRA on TGEV-induced inflammatory injury in intestinal porcine epithelial cells (IPEC-J2) and to explore the underlying molecular mechanism. We assumed that ATRA might inhibit inflammatory response by regulating NF-kB signaling pathways, and eventually attenuating TGEV-induced intestinal barrier damage.

siRNA Transfection of IPEC-J2 Cells
The siRNA targeting porcine TLR-3, TLR-7, RIG-I, MDA5 and negative control siRNA (siNC) were synthesized by Sangon Biotech Co., Ltd (Shanghai, China), and the target sequences were listed in Table 1. Cells were transfected with siRNA at indicated concentrations using lipofectamine 3000 (Invitrogen) according to the manufacturer's instructions. After transfection, the cells were used for subsequent analysis or treatment.

Cell Viability Assay
Cell viability was determined using a commercial CCK-8 kit (Beyotime Biotechnology, Shanghai, China) according to the manufacturer's instructions. Briefly, IPEC-J2 cells were cultured in 96-well plates at a density of 1×10 4 cells/well and treated with various concentrations of ATRA (0, 1, 10, 20, 40, 60, 80, 100 and 200 mM) at 37°C for 48 h. Then, 10 ul CCK-8 assay solution was added into each well for 2 h at 37°C. Finally, the optical density (OD) of each well at 450 nm was measured using a microplate reader (SpectraMax M2, Molecular Devices, Sunnyvale, CA, USA).

Lactate Dehydrogenase Activity Assay
To identify cell membrane damage, the activity of lactate dehydrogenase (LDH) in IPEC-J2 cells culture medium was detected by LDH assay kit (Nanjing Jiancheng Bioengineering Institute, Nanjing, China) following the manufacturer's instructions.

Cytokine Concentration Assay
The concentrations of IL-1b, IL-6, IL-8 and TNF-a in IPEC-J2 cells culture medium were determined by using the commercially ELISA kits (Jiangsu Meimian Biotechnology Co., Ltd., Jiangsu, China) according to the manufacturer's instructions.

RNA Extraction and Real-Time PCR
Total RNA was extracted from IPEC-J2 cells using TRIzol reagent (TaKaRa Biotechnology Co, Ltd, Dalian, China) following the manufacturer's instructions. The integrity of RNA was checked by electrophoresis on a 1.5% agarose gel. Complementary DNA (cDNA) was synthesized from 1µg of total RNA using the PrimeScripte RT reagent kit (Takara) according to the manufacturer's instructions. Then, the synthesized cDNA was diluted (1:4) and real-time quantitative PCR amplification was performed using SYBR Premix Ex TaqTM kits (TaKaRa) on the CFX96 Real-Time PCR Detection System (Bio-Rad). The primers were synthesized by TaKaRa Biotechnology Co, Ltd. (Dalian, China), which were listed in Table 2. The thermal cycling parameters were as follows: pre-denaturation at 95°C for 30s, then 40 cycles at 95°C for 5 s, 60°C for 34 s and extension at 72°C for 60 s. Each reaction was completed with a melting curve analysis to ensure the specificity of the reaction. The relative mRNA levels of target genes were analyzed using the 2 −DDCt method and using b-actin as the reference gene (25). All reactions were performed in triplicate.

Western Blot Analysis
Proteins from IPEC-J2 cell samples were acquired using RIPA lysis buffer containing PMSF and phosphatase inhibitor. After incubating at 4°C for 30 min, samples were homogenized and centrifuged at 12,000 g for 15 min at 4°C, and the supernatants were collected. The protein concentrations in the supernatants were determined by a BCA protein assay kit (Thermo Scientific, MA, USA). Then, equal amounts of protein (25 mg) were separated by 10% sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to polyvinylidene difluoride (PVDF) membranes (Merck Millipore Ltd., Tullagreen, Ireland). The membranes were blocked using 5% nonfat dry milk in 1× TBST for 1 h at room temperature followed by an overnight incubation at 4°C with indicated primary antibodies. Following three flushes with 1× TBST, the membranes were incubated with the corresponding HRP-conjugated secondary antibodies for 1 h at room temperature. Finally, the protein bands were visualized with ECL chemiluminescence kit (Beyotime Biotechnology, Shanghai, China) by the ChemiDoc ™ XRS Imager System (Bio-Rad). The protein band densities were quantified using Image Lab software (Bio-Rad).

Immunofluorescence Assay
IPEC-J2 cells were cultured in a 12-well cell culture plate and infected with TGEV at MOI of 1 for 1 h. Afterwards, the cells were washed with PBS and cultured with 80 mM ATRA for 36 h. After cell treatment, IPEC-J2 cells were fixed with cold 4% paraformaldehyde for 15 min and permeated with 0.05% Triton X-100 for 15 min at room temperature. Then, the IPEC-J2 cells were incubated with primary anti-NF-kB p65 mouse antibodies overnight at 4°C (1:100 dilution, Cell signaling Technology, USA). The cells were then washed with

Statistical Analysis
All data were presented as the means ± standard error of mean (SEM). Statistical differences were analyzed by the unpaired twotailed Student's t-test and/or one-way analysis of variance (ANOVA) using SPSS 22.0 statistics software (Chicago, IL, USA). P < 0.05 was considered statistically significant.

Effects of ATRA on the Viability of IPEC-J2 Cells
To investigate the cytotoxic effects of ATRA on IPEC-J2 cells, IPEC-J2 cells were treated with various concentrations of ATRA (0, 1, 10, 20, 40, 60, 80, 100 and 200 mM) for 48 h. As shown in Figure 1, ATRA concentrations ≤100 mM did not significantly affect cell viability (P > 0.05), but a marked decrease in cell viability was observed at ATRA concentration with 200 mM compared with the control group (P < 0.001). Therefore, an ATRA concentration range of 0~80 mM was used in the subsequent experiments.

ATRA Attenuated TGEV-Induced Inflammatory Response in IPEC-J2 Cells
To assess whether ATRA attenuated the inflammatory response induced by TGEV, the mRNA levels of the inflammatory cytokines were analyzed by real-time PCR. The results showed that TGEV infection significantly up-regulated the mRNA levels of IL-1b, IL-6, IL-8, TNF-a and IL-10 (P < 0.001), whereas ATRA treatment significantly inhibited the up-regulation of the gene expressions of inflammatory cytokines in a dose-dependent manner (P < 0.05). The highest concentration ATRA (80 mM) was the most effective in decreasing the mRNA expressions of inflammatory cytokines induced by TGEV (P < 0.001) ( Figure 2).
To further determine the effects of ATRA on the TGEV-induced inflammatory response, we detected the concentrations of inflammatory cytokines in IPEC-J2 cells culture medium. Compared with the control group, ATRA treatment significantly decreased the concentrations of IL-1b and IL-6 in IPEC-J2 cells   damage induced by TGEV, LDH activity in IPEC-J2 cell culture medium was detected. As shown in Figure 4A, compared with the control group, TGEV infection significantly increased the LDH activity in IPEC-J2 cells culture medium, whereas ATRA treatment significantly decreased LDH released from the TGEV-infected IPEC-J2 cells (P < 0.001). In addition, compared with the control group, ATRA treatment significantly increased Occludin protein level (P < 0.001). TGEV infection significantly reduced the protein levels of ZO-1 and Occludin compared with the control group (P < 0.001). However, ATRA treatment significantly reversed this reduction of ZO-1 and Occludin protein levels induced by TGEV (Pwfi 2 < 0.001) (Figures 4B-D).

ATRA Prevented TGEV-Induced NF-kB Signaling Pathway Activation in IPEC-J2 Cells
Compared with the control group, TGEV infection significantly upregulated the phosphorylation levels of IkBa and NF-kB p65 in IPEC-J2 cells (P < 0.001), whereas UV-inactivated TGEV treatment did not induce the upregulation of NF-kB p65 phosphorylation level in IPEC-J2 cells (P > 0.05). Furthermore, ATRA treatment significantly prevented the upregulation of IkBa and NF-kB p65 phosphorylation levels induced by TGEV (P < 0.01) (Figures 5A-E). Further immunofluorescence analysis found that TGEV infection induced the translocation of NF-kB p65 from cytoplasm to nucleus in IPEC-J2 cells, and ATRA treatment inhibited this process ( Figure 5F). These results indicated that TGEV infection could activate the NF-kB signaling pathway, and this ability required TGEV replication; ATRA treatment could prevent the NF-kB signaling pathway activation induced by TGEV.

ATRA Attenuated TGEV-Induced Inflammatory Response in IPEC-J2 Cells via Suppressing the NF-kB Signaling Pathway
To further investigate whether ATRA attenuated TGEV-induced inflammatory response via suppressing the NF-kB signaling pathway, the effect of ATRA was examined by using by NF-kB inhibitors (BAY11-7082). As shown in Figure 6, we found that TGEV infection significantly increased the phosphorylation level of NF-kB p65 in IPEC-J2 cells compared with the control group, whereas BAY11-7082 treatment significantly inhibited the enhancing of NF-kB p65 phosphorylation level induced by TGEV (P < 0.001). Furthermore, we found that TGEV infection significantly upregulated the mRNA levels of IL-1b, IL-6, IL-8, TNF-a and IL-10 in IPEC-J2 cells and increased the concentrations of IL-1b, IL-6, IL-8, TNF-a and IL-10 in IPEC-J2 cells culture medium compared with the control group (P < 0.05). However, BAY11-7082 treatment significantly inhibited the upregulation of IL-6, IL-8, TNF-a and IL-10 mRNA levels in IPEC-J2 cells and the enhancing of IL-1b, IL-6 and TNF-a concentrations in IPEC-J2 cells culture medium induced by TGEV (P < 0.05).

Effects of ATRA and TGEV on TLRs/RLRs Signaling Pathway in IPEC-J2 Cells
As shown in Figure 7, compared with the control group, ATRA treatment significantly increased the mRNA levels of TLR3, TLR4, TRIF and TRAF6 (P < 0.05). TGEV infection significantly upregulated the mRNA levels of TLR2, TLR3, TLR4, TLR7, MyD88, TRIF and TRAF6, and downregulated TLR9 mRNA level compared with the control group (P < 0.05). However, ATRA treatment significantly suppressed the upregulation of TLR3, TLR7, TRIF and TRAF6 mRNA levels and the downregulation of TLR9 mRNA level induced by TGEV (P < 0.01). Furthermore, TGEV infection significantly increased the protein levels of TLR3 and TLR7 compared with the control group, whereas ATRA treatment significantly inhibited the enhancing of TLR3 and TLR7 protein levels induced by TGEV (P < 0.01). As shown in Figure 8, the mRNA abundance of RIG-Ⅰ, MDA5 and MAVS was significantly upregulated in TGEV group compared with the control group, and ATRA treatment significantly inhibited the upregulation of RIG-Ⅰ, MDA5 and MAVS mRNA abundance induced by TGEV (P < 0.001). Furthermore, TGEV infection significantly increased the protein levels of RIG-I and MDA5 compared with the control group, whereas ATRA treatment significantly inhibited the enhancing of RIG-I and MDA5 protein levels induced by TGEV (P < 0.01).

ATRA Attenuated TGEV-Induced Inflammatory Response in IPEC-J2 Cells via Suppressing the RLRs/NF-kB Signaling Pathway
To further confirm whether ATRA attenuated TGEV-induced inflammatory response via suppressing the TLRs/RLRs/NF-kB signaling pathway, we used siRNAs targeting specific receptors to interfere with the signaling pathway. The knockdown efficiency of each siRNA was demonstrated by transfection and real-time PCR assays ( Figure 9A). The cells were transfected with specific siRNAs followed by infection with TGEV, then incubation with or without ATRA. As shown in Figures 9B, C, siRNAs targeting RIG-I and MDA5 but not TLR3 and TLR7 significantly reduced the phosphorylation level of NF-kB p65 in TGEV-infected cells (P < 0.01). Next, we further determine the effects of siRNAs on TGEV-induced inflammatory response. As shown in

DISCUSSION
Coronaviruses, a genus in the Coronaviridae family, constitute a significant threat to both human and animal health (26,27). Transmissible gastroenteritis virus (TGEV) is an enteropathogenic coronavirus, which causes severe diarrhea, vomiting and high mortality in piglets, resulting in heavy economic losses to the pig breeding industry (28). TGEV replicates in enterocytes covering the villi of the porcine small intestine, causing villus atrophy and crypt hyperplasia, and impairing the intestinal barrier in diseased piglets (29). The pathogenesis of TGEV infection is strongly associated with inflammation. Previous studies found The results indicated that ATRA can inhibit LPS-induced inflammatory response, but it is unclear whether ATRA can attenuate the inflammatory response induced by TGEV. In the present study, we found that ATRA treatment reduced the upregulation of inflammatory cytokines (IL-1b, IL-6, IL-8, TNF-a and IL-10) mRNA expressions induced by TGEV in a dosedependent manner. To further determine the effects of ATRA on the TGEV-induced inflammatory response, we detected the concentrations of inflammatory cytokines in cell culture medium. Our results found that ATRA treatment significantly inhibited the elevation of IL-1b, IL-6, TNF-a and IL-10 concentrations induced by TGEV. These results indicated that ATRA can attenuate TGEV-induced inflammatory response in IPEC-J2 cells.
The function of epithelial cells is based on the integrity of the epithelial barrier, and excessive production of proinflammatory cytokines might lead to the cell damage (32). LDH is an important indicator of the intestinal epithelial barrier integrity. It is known that LDH is released when the cells are damaged, so LDH release can indirectly reflect the permeability of cells (33). In the present study, TGEV infection significantly increased the LDH activity in IPEC-J2 cells culture medium, whereas ATRA treatment significantly decreased LDH released from the TGEVinfected IPEC-J2 cells. These results suggested that the ATRA treatment prevented the TGEV-induced enhancement of cell permeability. Tight junction (TJ) proteins [occludin, claudin, and intracellular plaque proteins (ZO and cingluin)] play important roles in maintaining the mechanical barrier and permeability of the mucosal epithelium (34). Studies have shown that proinflammatory cytokines (IL-1b, IL-6, IL-8 and TNF-a) could induce disruption of tight junction proteins, which led to the increasing of intestinal permeability (35). In the present study, consistent with overproduction of proinflammatory cytokines induced by TGEV, decreased ZO-1 and Occludin protein levels in TGEV-infected IPEC-J2 cells were observed. However, ATRA treatment significantly reversed the reduction of ZO-1 and Occludin protein levels induced by TGEV. Similar results also reported that ATRA treatment significantly suppressed the downregulation of ZO-1, Occludin and Claudin-1 protein levels induced by LPS in IPEC-J2 (18). These results indicated that ATRA may attenuate TGEVinduced epithelial barrier integrity damage in IPEC-J2 cells via suppressing inflammatory response.
To further study the mechanism by which ATRA suppress TGEV-induced inflammatory response in IPEC-J2 cells, we detected NF-kB signaling pathway. NF-kB is a major transcription factor that plays an essential role in inflammatory response. In the stimulated state, IkBa gets phosphorylated and dissociated from NF-kB, and then NF-kB gets phosphorylated and migrates into the nucleus to promote the release of proinflammatory cytokines (36,37). Wang et al. reported that TGEV infection promoted the phosphorylation of NF-kB p65 and nuclear translocation of NF-kB p65, and leading to an increase in pro-inflammatory cytokines mRNA expressions in IPEC-J2 and ST cells (9). In the present study, TGEV infection significantly upregulated the phosphorylation levels of IkBa and NF-kB p65, and induced the translocation of NF-kB p65 from cytoplasm to nucleus in IPEC-J2 cells, while ATRA treatment inhibited this process. These results indicated that ATRA can inhibit TGEV-induced NF-kB signaling pathway activation. To further investigate whether ATRA alleviated TGEV-induced inflammatory response via suppressing the NF-kB signaling pathway, we used the NF-kB specific inhibitors (BAY11-7082) to inhibit NF-kB activation in TGEVinfected IPEC-J2 cells. Our results found that BAY11-7082 treatment significantly inhibited the enhancing of NF-kB p65 phosphorylation level induced by TGEV. Furthermore, we found that BAY11-7082 treatment significantly inhibited the upregulation of pro-inflammatory cytokines (IL-1b, IL-6, IL-8 or TNF-a) levels induced by TGEV. These results indicated that ATRA may attenuate TGEV-induced inflammatory response via suppressing the NF-kB signaling pathway. However, the underlying mechanisms of how ATRA negatively regulated the NF-kB signaling pathway remain unclear. At present, Toll-like receptors (TLRs), and RIG-I-like receptors (RLRs) are the two main pattern recognition receptors (PRRs) for detecting viral pathogen-associated molecular patterns (PAMPs) (38). After the virus recognizes PRRs, these receptors recruit specific intracellular adaptor proteins (MyD88, TRIF or MAVS) to trigger downstream signaling events, thereby activating NF-kB and inducing the production of inflammatory cytokines (39,40). Previous studies have shown PEDV virus and herpesvirus can induce NF-kB activation by the TLRs-mediated signaling pathway (41,42). In the present study, TGEV infection significantly upregulated the mRNA levels of TLR2, TLR3, TLR4, TLR7 and their downstream signaling molecules MyD88, TRIF and TRAF6. However, ATRA treatment significantly suppressed the upregulation of TLR3, TLR7, TRIF and TRAF6 mRNA levels induced by TGEV. Furthermore, we found that ATRA treatment significantly inhibited the enhancing of TLR3 and TLR7 protein levels induced by TGEV. These results indicated that ATRA may suppress the TLR3 and TLR7 signaling pathway in TGEV-infected IPEC-J2 cells. Moreover, Zhen et al. reported that TGEV infection induces NF-kB activation through RLRs-mediated signaling pathway (43). In the present study, we also found that TGEV infection significantly increased the mRNA abundance of RIG-I, MDA5 and MAVS. However, ATRA treatment significantly inhibited the enhancing of RIG-I, MDA5 and MAVS mRNA abundance induced by TGEV. We further researched and found that ATRA treatment significantly inhibited the enhancing of RIG-I and MDA5 protein levels induced by TGEV. These results indicated that ATRA may suppress the RLRs signaling pathway in TGEV-infected IPEC-J2 cells. To further confirm whether ATRA alleviated TGEV-induced inflammatory response via suppressing the TLRs/RLRs/NF-kB signaling pathway, we used siRNAs targeting specific receptors to interfere with the signaling pathways. Our studies showed that TLR3 and TLR7 knockdown did not impede TGEV-induced NF-kB activation; however, RIG-I and MDA5 knockdown clearly suppressed TGEV-induced NF-kB activation. These results indicated that ATRA attenuated TGEVinduced NF-kB activation via suppressing the RLRs signaling pathway. Next, we further determine the effects of siRNAs on TGEV-induced inflammatory response. Our results found that siRNAs targeting RIG-I and MDA5 but not TLR3 and TLR7 significantly reduced the mRNA expressions and concentrations of pro-inflammatory cytokines (IL-1b, IL-6, IL-8 or TNF-a) in TGEV-infected cells. The above results suggested that ATRA alleviated TGEV-induced inflammatory response via suppressing the RLRs/NF-kB signaling pathway.
In conclusion, our results indicated that ATRA attenuated TGEV-induced IPEC-J2 cells damage via suppressing inflammatory response, the mechanism of which is associated with the inhibition of TGEV-mediated activation of RLRs/ NF-kB signaling pathway Figure 10. These results provide a scientific basis for considering ATRA as a potential therapeutic agent against TGEV infection in the future.

DATA AVAILABILITY STATEMENT
The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.